TREATMENT OF PYOINFLAMMATORY COMPLICATIONS WITH INDIVIDUALLY SELECTED OZONE DOSE IN PATIENTS WITH DIABETES

Georgian Med News. 2018 Feb:(Issue):91-94.

Abstract

The severity of purulent-inflammatory process in patients with diabetes mellitus is determined by lymphocytotoxic test. The test shows that application of intravenous ozone therapy with individually selected ozone dose significantly decreases the spread of necrotic suppurative focus already on the third day of treatment. Granulation tissue and marginal epithelization in the wound develops on the 6-8th day of hospitalization; normalization of glycemic levels shorten of the period of the hospital stay up to 3-5 days, compared to the control group.

MeSH terms

  • Alprostadil / therapeutic use
  • Amputation, Surgical / methods
  • Anti-Inflammatory Agents / therapeutic use
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / pathology
  • Diabetes Mellitus / surgery
  • Diabetic Foot / blood
  • Diabetic Foot / drug therapy*
  • Diabetic Foot / pathology
  • Diabetic Foot / surgery
  • Drug Administration Schedule
  • Heparin / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use*
  • Niacin / therapeutic use
  • Ozone / therapeutic use*
  • Pentoxifylline / therapeutic use
  • Suppuration / blood
  • Suppuration / drug therapy*
  • Suppuration / pathology
  • Suppuration / surgery

Substances

  • Anti-Inflammatory Agents
  • Blood Glucose
  • Immunologic Factors
  • Niacin
  • Ozone
  • Heparin
  • Alprostadil
  • Pentoxifylline